



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number : 0 348 442 B1

BD

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification :
27.01.93 Bulletin 93/04

(61) Int. Cl.⁵ : **A61K 39/395, C12P 21/00,
C12N 15/20**

(21) Application number : **88907757.4**

(22) Date of filing : **05.09.88**

(86) International application number :
PCT/GB88/00729

(87) International publication number :
WO 89/01782 09.03.89 Gazette 89/06

(54) ALTERED ANTIBODY.

(30) Priority : **04.09.87 GB 8720833**

(43) Date of publication of application :
03.01.90 Bulletin 90/01

(45) Publication of the grant of the patent :
27.01.93 Bulletin 93/04

(84) Designated Contracting States :
AT BE CH DE FR GB IT LI LU NL SE

(56) References cited :
None

(73) Proprietor : **CELLTECH LIMITED
216 Bath Road
Slough Berkshire SL1 4EN (GB)**

(72) Inventor : **BODMER, Mark, William
131 Reading Road Henley-on-Thames
Oxfordshire RG19 1DJ (GB)**
Inventor : **ADAIR, John, Robert
23 George Road Stokenchurch
High Wycombe HP14 3RN (GB)**
Inventor : **WHITTLE, Nigel, Richard
5 Leigh Road Cobham
Surrey KT11 2LF (GB)**
Inventor : **LYONS, Alan, Howard
15 Beaumont Close Woodlands Park
Maidenhead SL6 3XN (GB)**
Inventor : **OWENS, Raymond, John
23 Hamilton Avenue Henley-on-Thames
Oxfordshire RG9 1SH (GB)**

(74) Representative : **Mercer, Christopher Paul et al
Carpmaels & Ransford 43, Bloomsbury Square
London WC1A 2RA (GB)**

EP 0 348 442 B1

Note : Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

The present invention relates to an altered antibody molecule having therein a specific thiol group for use in attachment to the antibody molecule of effector or reporter molecules and to a process for its production using recombinant DNA technology.

In the present application:

the term "MAb" is used to indicate a monoclonal antibody;

the term "recombinant antibody molecule" (RAM) is used to describe an antibody produced by any process involving the use of recombinant DNA technology, including any analogues of natural immunoglobulins or their fragments; and

the term "humanised antibody molecule" (HAM) is used to describe a molecule having an antigen binding site derived from an immunoglobulin from a non-human species, the remaining immunoglobulin-derived parts of the molecule being derived from a human immunoglobulin. In a HAM the antigen binding site may comprise either complete variable domains fused onto constant domains or only the complementarity determining regions grafted onto appropriate framework regions in the variable domains.

In the description, reference is made to a number of publications by number. The publications are listed in numerical order at the end of the description.

Natural immunoglobulins have been known for many years, as have the various fragments thereof, such as the Fab, (Fab')₂ and Fc fragments, which can be derived by enzymatic cleavage. Natural immunoglobulins comprise a generally Y-shaped molecule having an antigen-binding site at the end of each arm. The remainder of the structure, and particularly the stem of the Y, mediates the effector functions associated with immunoglobulins.

Natural immunoglobulins have been used in diagnosis and, to a more limited extent, in therapy. However, such uses, especially in therapy, have been hindered by the polyclonal nature of natural immunoglobulins. A significant step towards the realisation of the potential of immunoglobulins as therapeutic agents was the discovery of monoclonal antibodies (1) of defined antigen specificity. Most MAbs are produced by fusions of rodent spleen cells with rodent myeloma cells. They are therefore essentially rodent MAbs. There are very few reports of the production of human MAbs.

There have been made proposals for making non-human MAbs less antigenic in humans. Such techniques can be generically termed "humanizing" MAbs. These techniques generally involve the use of recombinant DNA technology to manipulate DNA sequences encoding the polypeptide chains of the antibody molecule.

Some early methods for carrying out such a procedure are described in EP-A-0 171 496 (Res. Dev. Corp. Japan), EP-A-0 173 494 (Stanford University), EP-A-0 194 276 (Celltech Limited) and WO-A-8 702 671 (Int. Gen. Eng. Inc.).

In an alternative approach, described in EP-A-87302620.7 (Winter), the complementarity determining regions (CDRs) of a mouse MAb have been grafted onto the framework regions of the variable domains of a human immunoglobulin by site directed mutagenesis using long oligonucleotides.

It has been widely suggested that immunoglobulins, and in particular MAbs, could potentially be very useful in the diagnosis and treatment of cancer (2,3). There has therefore been much activity in trying to produce immunoglobulins or MAbs directed against tumour-specific antigens. So far, over one hundred MAbs directed against a variety of human carcinomas have been used in various aspects of tumour diagnosis or treatment (4).

In our copending application No. WO 89/01783 also claiming priority from British patent application No. 8720833, there is described a humanised antibody molecule (HAM) having an antigen binding site wherein at least the complementarity determining regions (CDRs) of the variable domain are derived from the mouse monoclonal antibody B72.3 (B72.3 MAb) and the remaining immunoglobulin-derived parts of the HAM are derived from a human immunoglobulin. The B72.3 MAb is a mouse MAb of the type IgG1 raised against a membrane-enriched extract of a human liver metastasis of a breast carcinoma (5). The B72.3 MAb has been extensively studied in a number of laboratories. It has been shown to recognise a tumour-associated glycoprotein TAG-72, a mucin-like molecule with a molecular weight of approximately 10⁶ (6). Immunohistochemical studies have demonstrated that the B72.3 MAb recognises approximately 90% of colorectal carcinomas, 85% of breast carcinomas and 95% of ovarian carcinomas. However, it shows no significant cross-reactivity with a wide spectrum of normal human tissues (7 to 10).

In order to increase the efficacy of immunoglobulin molecules as diagnostic or therapeutic agents, it has been proposed that effector or reporter molecules should be covalently linked thereto. However, this is not always possible to carry out conveniently. For instance, a potential site of attachment is a thiol group. Thiol groups occur naturally in proteins as cysteine residues. However, such residues are relatively uncommon, are often inside the molecule and are frequently involved in forming disulphide bridges within or between protein mole-

cules. There is therefore a danger that, if any naturally occurring cystein residue is used as a site of attachment, it will interfere with the normal folding and stabilization of the protein.

It has therefore been proposed that other side chains on a protein molecule be modified to produce a thiol group. For instance, lysine residues can be chemically modified to produce a thiol group on their side chains. However, this process will produce a thiol group on many or all available such lysine residues. It is therefore likely that there will be multiple possible attachment sites, making it impossible to determine in advance where any attachment will take place. Moreover, multiple attachment may cause interference with the biological activity of the protein. Further, with a number of extra thiol groups, it is possible that the new thiol groups will form inter- or intra-chain disulphide bonds which will alter the configuration and function of the protein.

It has also been proposed that the effector or reporter molecules may be attached by specific labelling of the carbohydrate moieties of immunoglobulins (11). This generally involves periodate oxidation of the sugar residues to produce active aldehydes. However, this procedure has its disadvantages, in that the oxidation may also modify amino acids in the protein chains. For instance, methionine residues are readily oxidised. Moreover, the carbohydrate moieties are all located in the Fc portion of the immunoglobulin molecule. Therefore, it is not possible to use this method to label Fab or (Fab')₂ fragments of immunoglobulins.

It would therefore be desirable to provide a method by which effector or reporter molecules can be reproducibly and effectively attached to an immunoglobulin molecule in a site specific manner.

According to a first aspect of the present invention, there is provided an altered antibody molecule wherein a preselected residue in a surface pocket on the molecule has been changed to a cysteine residue to introduce a thiol group in said surface pocket at such a position as to enable an effector or reporter molecule to be attached thereto.

It will be understood by the skilled person that any protein molecule in its natural state adopts a folded configuration. Thus, the side chains of some of the amino acid residues are inside the folded protein and some are on the outside. Of those which are outside, some are located on convex surfaces, some on flat surfaces and some on concave surfaces. The concave surfaces are also described as pockets.

The skilled person would realise that the side chain of a residue on a flat or convex surface would probably protrude above the remainder of the protein. It would therefore be expected that, if such a residue were to be changed to a cysteine residue, the thiol group would be available for bonding to an effector or reporter molecule. Surprisingly, and contrary to this expectation, it has been found that if thiol groups are introduced in such positions, they are not available for such bonding. It would also be expected that a thiol group introduced as a side chain on an amino acid in a pocket would not be available for such bonding. However, surprisingly and contrary to this expectation, it has been found that such thiol groups are available and can be used to bond effect and reporter molecules to the antibody molecule. It may also have been expected that the introduction of such a thiol group would have grossly altered the macromolecular structure of the protein. Again, surprisingly and unexpectedly, it is found that this does not take place.

The altered antibody molecule of the present invention may comprise: a complete antibody molecule, having full length heavy and light chains; a fragment thereof, such as the Fab or (Fab')₂ fragment; or a light chain or heavy chain dimer so long as such a molecule has a thiol group introduced at a specified site and available for bonding.

In connection with this invention, "bonding" means forming covalent bonds to the thiol group of the cysteine residue.

It is envisaged that the altered antibody molecule may be produced by conventional peptide synthesis. However, it is preferred that the altered antibody molecule is produced by recombinant DNA technology.

According to a second aspect of the present invention, there is provided a process for preparing an altered antibody molecule according to the first aspect of the invention, which process comprises:

(a) producing an expression vector which contains an operon encoding at least one chain of a recombinant antibody molecule in which the sequence encoding a preselected amino acid residue located in a surface pocket of the chain has been altered so that the amino acid residue encoded by the altered sequence is a cysteine residue;

(b) transfecting a cell line with the vector; and

(c) culturing the transfected cell line to produce a recombinant antibody molecule of altered bonding ability.

If desired, two or more amino acid residues in a single polypeptide chain may be altered, or one or more amino acid residues in each of the two chains may be altered.

Preferably, the sequence alteration(s) is (are) carried out by site directed mutagenesis.

An essential feature of this aspect of the invention is the selection of the position of the amino acid residue which is to be altered. Since it is desired to introduce a thiol group, as the side chain of a cysteine residue, to enable an effector or reporter molecule to be attached to the RAM, it is desirable that:

(i) the side chain of the amino-acid to be altered should be of a similar size to that of the cysteine residue;

- (ii) there are no intra-chain hydrogen bonds with the residue to be altered;
 (iii) there are no intra-chain hydrogen bonds which could form with the cysteine residue;
 (iv) the thiol group should not be able to interact with or be hidden by any other parts of the RAM; and
 (v) the cysteine residue can only be accessed by small molecules, for instance of about 0.13 nm diameter,
 and not by molecules of larger size, for instance of greater than 0.5 nm diameter. Thus, the cysteine residue
 will only be available for bonding to the effector or reporter molecule and not to similar cysteine residues
 on the same or other chains.

The first three conditions will ensure, as far as possible, that the alteration to the new amino acid residue does not have any adverse effect on the conformation and stability of the RAM. The second two criteria ensure, as far as possible, that the thiol group will be available for bonding, but only to the effector or reporter molecule, and not to other similarly altered chains, thus preventing cross-linking by disulphide bonding. Residues which fulfil the requirement of (i) include threonine and serine. Thus, preferably, the residue(s) which is altered is a serine or threonine residue in a surface pocket of the immunoglobulin molecule.

A preferred site for carrying out such alteration is the CH1 domain, since alterations here and bonding of molecules thereto is unlikely to interfere with antigen binding or with the effector functions of the Fc portion (if present) of the altered antibody molecule. Advantageously, the residue in the CH1 domain which is altered is Ser 156 or Thr 173 (according to the numbering system set forth by Kabat et al. (14)). However, suitable sites for alteration may be found in any of the domains of the antibody molecule.

If desired, the antibody which is to be altered may be a "humanised" antibody produced by either of the methods referred to above

In the process of the second aspect of the present invention, if the vector encodes only a single antibody polypeptide chain, the product of the process will be a dimeric molecule. If a tetrameric molecule, similar to a natural immunoglobulin, is required, one of two alternative strategies may be employed.

In the first alternative, the cell line may also be transfected with a second vector, the first vector encoding a heavy chain-derived polypeptide and the second vector encoding a complementary light chain-derived polypeptide. Preferably, the vectors are identical except in so far as the coding sequences and selectable markers are concerned so as to ensure as far as possible that each polypeptide chain is equally expressed.

In the second alternative, the vector may include sequences coding for complementary light chain- and heavy chain-derived polypeptides.

If the vector encodes only a heavy chain polypeptide, it is also possible to produce a recombinant antibody molecule by using a host cell which naturally secretes a complementary light chain.

The present invention also includes cloning and expression vectors and transfected cell lines used in the process of the invention, therapeutic and diagnostic compositions containing the altered molecule of the invention and uses of such compositions in therapy and diagnosis.

Reporter or effector molecules may be attached to the altered antibody molecule by any convenient method.

The general methods by which the vectors may be constructed, transfection methods and culture methods are well known per se and form no part of the invention. Such methods are shown, for instance, in references 12 and 13.

The present invention is now described, by way of example only, with reference to the accompanying drawings which shows the DNA and amino acid sequence of the B72.3 HAM CH1 domain of a humanised B72.3 antibody molecule together with the sequences of 8 oligonucleotide primers used for site directed mutagenesis.

In our copending application No. WO 89/01783 referred to above, there is described the production of humanised B72.3 MAbs having various human IgG heavy chain domains. The application also shows the production of humanised B72.3 F(ab')₂ fragments. The results set out hereafter were obtained by use of the humanised B72.3 MAbs as shown in the copending application.

The nucleotide sequence and amino acid sequence of the CH1 domain of the humanised B72.3 molecule is shown in the drawing, to which reference is now made. In order to enable the humanised B72.3 antibody molecule to be bound to an effector or reporter molecule via a covalent linkage, a search was carried out for any serine or threonine residues located in a surface pocket and which satisfied the criteria set out as (i) to (v) previously. For the sake of comparison, other serine or threonine residues not meeting all the criteria were also selected.

The CH1 domain of the B72.3 molecule shows considerable sequence homology with that of the human antibody KOL. The KOL antibody is described by Kabat et al. (14). A crystal structure for the KOL antibody has been determined by x-ray crystallography. By making the necessary amino acid substitutions, it is possible to predict the structure of the B72.3 CH1 domain on the basis of the structure of the KOL CH1 domain.

On the basis of this prediction, a number of serine and threonine residues were selected. All were predicted to be located on the surface of the humanised B72.3 molecule, but it was predicted that some would be in pock-

ets, some on flat surfaces and some on convex surfaces. The target residues were identified as Thr 153; Ser 158; Ser 163; Thr 167; Ser 168; Thr 173; Thr 205; and Thr 217. The residue numbering used herein corresponds to that set forth by Kabat et al. (14).

5 Oligonucleotide primers for use in site directed mutagenesis experiments according to the gapped - duplex method (15) were produced. These are shown in the drawing. In each case, the primer was designed to effect a change of one of the above threonine or serine residues to a cysteine residue. The altered DNA vectors have now been produced and sequenced by the chain termination procedure (16).

10 All altered gene fragments were subsequently recloned into plasmid pEE6.HCMV (17) for expression in mammalian cell systems. This plasmid contains the strong promoter/enhancer transcriptional control element from human cytomegalovirus (17). Five of the original eight proposed cysteine mutants, namely numbers 1, 3, 4, 6 and 7, were taken to this stage.

15 The synthesis and functional assembly of the altered humanised B72.3 antibodies were analysed by transient expression in COS cells (17). Each of the five heavy chain mutant genes were transfected into the cells together with the humanised B72.3 light chain gene. Cell supernatants were assayed for B72.3 antigen binding activity using an ELISA assay. Secretion and assembly of immunoglobulins was also evaluated by biosynthetic labelling and immunoprecipitation of the transfected COS cells. The results of both types of analysis showed that all five thiol mutant genes produced fully assembled tetrameric antibody molecules whose antigen binding properties were indistinguishable from the unaltered humanised B72.3 molecule. None of the mutants appeared to produce aggregated molecules.

20 The transient expression system did not produce sufficient amounts of the antibodies for more detailed biochemical characterisation. Thus stable cell lines expressing the modified B72.3 antibodies were established. The mutant heavy chain genes were transfected by electroporation into a Chinese hamster ovary (CHO) cell line which already produced the humanised B72.3 light chain. Transfected cell lines were selected using a drug resistance marker incorporated into the pEE6.HCMV plasmid and cells producing altered B72.3 antibody were cloned and expanded.

25 Recombinant antibodies (both unmodified and thiol mutants) were purified from CHO cell supernatants by affinity chromatography on protein A-sepharose and concentrated by ultrafiltration. Purified antibodies were shown to be fully assembled and non-aggregated by SDS-polyacrylamide gel electrophoresis and gel filtration HPLC, confirming the results of the transient expression experiments. Antigen binding was demonstrated by ELISA. Collectively these results showed that substituting single cysteine residues at the surface of the CH1 domain of the heavy chain had not affected the synthesis, assembly and antigen binding activities of the altered antibodies. This appeared to be irrespective of the topographical position of the introduced thiol since all the mutants analysed behaved the same.

30 Since each immunoglobulin molecule comprises two heavy chains, the altered antibodies should have two free thiols if the cysteines remained in a reduced form. The redox state of the surface cysteines was measured by titration using 4,4'-dithiodipyridine. Antibody samples (0.5 mg/ml) were added to 4,4'-dithiodipyridine (0.5 mM final concentration) and reaction with free thiol groups was monitored by an increase in absorbance at 324 nm. The results are summarised in the following table.

40

45

50

55

TABLE

5 Titration of free-SH groups on humanis d B72.3 thiol
mutants.

	Mutant No.	Position	No. free thiols
10	1	pocket	0.97
15	3	convex	0.30
15	4	flat	0.30
15	6	pocket	1.10
15	7	flat	0.30
20	B72.3	control	0.30

25 Mutants 3, 4 and 7 have approximately the same values for the number of free thiol groups as the unaltered humanised B72.3 control, indicating that the introduced cysteines are not available for bonding. It is conjectured that they are most probably blocked in some way, for example by reaction with glutathione in vivo or in vitro. On the other hand, mutants 1 and 6 gave titration levels significantly greater than the control, corresponding to at least one free thiol group per antibody molecule. The discrepancy between this and the expected value of two thiols per antibody suggested that some oxidation of the thiols may have occurred.

30 However, the results showed that cysteines positioned at flat (mutants 4 and 7) or convex (mutant 3) surfaces, i.e. with relatively high contact surface accessibility, would not be suitable for site-specific attachment since their thiol groups appear to be blocked. By contrast the two cysteines located in pocket sites (mutants 1 and 6) remain in a form available for bonding to the extent of at least one free thiol per antibody molecule.

35 To investigate whether the mutants shown to have free thiols could be used for site-specific attachment of a reporter or effector molecule, a thiol specific linker was synthesised. Tyrosineamide (0.1 mmol in 0.5M pipes buffer, pH 6.8) was reacted with N-succinimidyl-3-maleimidopropionate (.015 mmol in 1,4-dioxane) to give 2-(3-N-maleimidyl)-N-propylamido-3-(4-hydroxy)phenylpropanoamide. This ligand is referred to as tyrosine maleimide and was labelled with ¹²⁵Iodine using chloramine T. The radioactive compound was purified by reverse phase HPLC. One of the thiol mutants (No. 6) was incubated with the iodinated probe (1 h, pH 5.5 at room temp.). Labelled antibody was separated from unincorporated ligand by either gel filtration or protein A-sepharose precipitation and analysed by SDS-polyacrylamide gel electrophoresis/auto-radiography. Both humanised and hybridoma-derived mouse B72.3 were included as negative controls.

40 Humanised B72.3 that had been reacted with 2-iminothiolane, which non-selectively introduces thiol groups onto lysine residues, was used as a positive control for the labelling procedure. The results of this analysis showed as expected that the thiol specific ligand tyrosine maleimide only labelled the heavy chain of the thiol mutant B72.3. By contrast the non-specifically modified humanised B72.3 was labelled on both heavy and light chains and also produced a number of aggregated molecules. Thus the site-specifically labelled antibody produced a more homogeneous product.

45 The process described above shows that cysteine residue may be substituted into the heavy chain of an antibody molecule in such a position that reporter molecule may be site-specifically attached to that antibody molecule through the introduced thiol. It shows that the thiol group must be introduced into a surface pocket in order for it to be able effectively to bond to the effector or reporter molecule.

50 It will be appreciated that the same procedure may be carried out on a different domain of the heavy or light chain of an antibody molecule. All that is necessary is to locate a suitable surface pocket site having therein an appropriate amino acid residue.

55 It will be appreciated that the present invention has been described above by way of illustration only, and that variations or modifications of detail can be made without departing from the scope of the invention.

References

- 5 1. Kohler & Milstein, *Nature*, 265, 495-497, 1975.
 2. Ehrlich, P., *Collected Studies on Immunity*, 2, John Wiley & Sons, New York, 1906.
 3. Levy & Miller, *Ann.Rev.Med.*, 34, 107-116, 1983.
 4. Schliom & Weeks, *Important Advances in Oncology*, 170-192, Wippincott, Philadelphia, 1985.
 5. Colcher et al., *PNAS*, 78, 3199-3203, 1981.
 6. Johnson et al., *Cancer Res.*, 46, 850-897, 1986.
 7. Stramignoni et al., *Int.J.Cancer*, 31, 543,552, 1983.
 10 8. Nuti et al., *Int.J.Cancer*, 29, 539-545, 1982.
 9. Thor et al., *J.Nat.Cancer Inst.*, 76, 995-1006, 1986.
 10. Thor et al., *Cancer Res.*, 46, 3118-3124, 1986.
 11. O'Shannessy & Quarles, *J. Immunol. Methods*, 99, 153-161, 1987.
 12. Maniatis et al., *Molecular Cloning*, Cold Spring Harbor, New York, 1982.
 15 13. Primrose and Old, *Principles of Gene Manipulation*, Blackwell, Oxford, 1980.
 14. Kabat et al., *Sequences of Proteins of Immunological Interest*, Fourth Edition, U.S. Dept. of Health and Human Services, 1987.
 15. Boshart et al., *Cell*, 41, 521-530, 1985.
 16. Sanger et al., *PNAS*, 74, 5463-5467, 1977.
 20 17. Whittle et al., *Prot. Eng.*, 1, 6, 499-530, 1985

Claims

- 25 1. An altered antibody molecule wherein a preselected residue in a surface pocket on the molecule has been changed to a cysteine residue to introduce a thiol group in said surface pocket at such a position as to enable an effector or reporter molecule to be attached thereto.
 2. The altered antibody molecule of claim 1, which is made by recombinant DNA technology.
 30 3. The altered antibody molecule of claim 1 or claim 2, which is a complete antibody molecule, an Fab fragment or an F(ab')₂ fragment.
 4. The altered antibody molecule of any one of claims 1 to 3, wherein the alteration is in the CH1 domain.
 35 5. The altered antibody molecule of claim 4, wherein the altered residue is Ser 156 or Thr 173.
 6. A process for preparing an altered antibody molecule according to claim 2 or any claim dependent thereon, which process comprises:
 (a) producing an expression vector which contains an operon encoding at least one chain of a recombinant antibody molecule in which the sequence encoding a preselected amino acid residue located in a surface pocket of the chain has been altered so that the amino acid residue encoded by the altered sequence is a cysteine residue;
 (b) transfected a cell line with the vector; and
 (c) culturing the transferred cell line to produce a recombinant antibody molecule of altered bonding ability.
 45 7. The process of claim 6, in which the alteration is carried out by site directed mutagenesis.
 8. The process of claim 6, wherein the cell line is also transformed with a second vector, the first vector encoding a heavy chain-derived polypeptide and the second vector encoding a complementary light-chain derived polypeptide.
 9. The process of claim 6, wherein the expression vector includes sequences coding for complementary light- and heavy- chain derived polypeptides.

Patentansprüch

1. Verändertes Antikörpermolekül, bei welchem ein vorher ausgewählter Rest in einer Oberflächentasche auf dem Molekül in einen Cysteinrest umgewandelt wurde, um ein Thiolgruppe in diese Oberflächentasche in einer solchen Position einzuführen, daß ein Effektor- oder Reportermolekül daran gebunden werden kann.
2. Verändertes Antikörpermolekül nach Anspruch 1, das durch rekombinante DNA-Technologie hergestellt wurde.
3. Verändertes Antikörpermolekül nach Anspruch 1 oder 2, das ein komplettes Antikörpermolekül, ein Fab-Fragment oder ein F(ab')₂-Fragment ist.
4. Verändertes Antikörpermolekül nach einem der Ansprüche 1 bis 3, bei welchem die Veränderung in solche im CH1-Bereich ist.
5. Verändertes Antikörpermolekül nach Anspruch 4, bei welchem der veränderte Rest Ser 156 oder Thr 173 ist.
6. Verfahren zur Herstellung eines veränderten Antikörpermoleküls nach Anspruch 2 oder irgendeinem davon abhängigen Anspruch, welches Verfahren umfaßt:
 - (a) die Herstellung eines Expressionsvektors, der ein Operon enthält, das für zumindest eine Kette eines rekombinanten Antikörpermoleküls codiert, in welchem die für einen vorher ausgewählten, in der Oberflächentasche der Kette lokalisierten Aminosäurerest codierende Sequenz so verändert wurde, daß der durch die veränderte Sequenz codierte Aminosäurerest ein Cysteinrest ist;
 - (b) die Transfektion einer Zell-Linie mit dem Vektor; und
 - (c) die Züchtung der transfizierten Zell-Linie zur Herstellung eines rekombinanten Antikörpermoleküls mit veränderter Bindungsfähigkeit.
7. Verfahren nach Anspruch 6, bei welchem die Veränderung durch stellengenekte Mutagenese erhalten wird.
8. Verfahren nach Anspruch 6, bei welchem die Zell-Linie auch mit einem zweiten Vektor transformiert wird, wobei der erste Vektor für ein von einer schweren Kette abgeleitetes Polypeptid und der zweite Vektor für ein von einer komplementären leichten Kette abgeleitetes Polypeptid codiert.
9. Verfahren nach Anspruch 6, bei welchem der Expressionsvektor Sequenzen enthält, die für von komplementären leichten Ketten und schweren Ketten abgeleitete Polypeptide codieren.

Revendications

1. Molécule d'anticorps modifiée, dans laquelle un résidu choisi au préalable dans une poche superficielle sur la molécule a été transformé en un résidu cystéine pour l'introduction d'un groupe thiol dans ladite poche superficielle en une position permettant à une molécule effectrice ou reporter d'être fixée à celle-ci.
2. Molécule d'anticorps modifiée selon la revendication 1, qui est produite par la technologie de l'ADN recombinant.
3. Molécule d'anticorps modifiée selon la revendication 1 ou 2, qui est une molécule d'anticorps complète, un fragment Fab ou un fragment F(ab')₂.
4. Molécule d'anticorps modifiée selon l'une quelconque des revendications 1 à 3, dans laquelle la modification est dans le domaine CH1.
5. Molécule d'anticorps modifiée selon la revendication 4, dans laquelle le résidu modifié est Ser 156 ou Thr 173.
6. Procédé pour la production d'une molécule d'anticorps modifiée selon la revendication 2 ou l'une quel-

conqu des revendications dépendantes de celle-ci, lequel procédé comprend:

- (a) la production d'un vecteur d'expression qui contient un opéron codant pour au moins une chaîne d'une molécule d'anticorps recombinant, dans lequel la séquence codant pour un résidu aminoacide choisi au préalable, situé dans une poche superficielle de la chaîne, a été modifiée de manière que le résidu aminoacide codé par la séquence modifiée soit un résidu cystéine;
- (b) la transfection d'une lignée cellulaire par le vecteur; et
- (c) la culture de la lignée cellulaire transfectée, pour la production d'une molécule d'anticorps recombinant à capacité de fixation modifiée.

- 5 7. Procédé selon la revendication 6, dans lequel la modification est effectuée par mutagénèse dirigée sur un site.
- 10 8. Procédé selon la revendication 6, dans lequel la lignée cellulaire est également transformée par un second vecteur, le premier vecteur codant pour un polypeptide dérivé de chaîne lourde et le second vecteur codant pour un polypeptide dérivé de chaîne légère complémentaire.
- 15 9. Procédé selon la revendication 6, dans lequel le vecteur d'expression comprend des séquences codant pour des polypeptides dérivés de chaînes légère et lourde complémentaires.

20

25

30

35

40

45

50

55

A

	4	1	2	53
	*	*	*	**
G4chi	ASTKGPSVFP LAPCSA	STSE STAALGCLVK	DYFPEPVTVS	WNSGALTSGV
G3chi	ASTKGPSVFP LAPCSA	STSG GTAALGCLVK	DYFPEPVTVS	WNSGALTSGV
G2chi	ASTKGPSVFP LAPCSA	STSE STAALGCLVK	DYFPEPVTVS	WNSGALTSGV
G1chi	ASTKGPSVFP LAPSSK	STSG GTAALGCLVK	DYFPEPVTVS	WNSGALTSGV
	6	7	8	
	*	*	*	
G4chi	HTFPAVLQSS GLYS	LSSVVT VPSSSLGTKT	YTCNVDHKPS	NTKVOKAV
G3chi	HTFPAVLQSS GLYS	LSSVVT VPSSSLGTQT	YTCNVNHKPS	NTKVOKAV
G2chi	HTFPAVLQSS GLYS	LSSVVT VPSSNFGTQT	YTCNVHKPS	NTKVOKTV
G1chi	HTFPAVLQSS GLYS	LSSVVT VPSSSLGTQT	YICNVNHKPS	NTKVOKKV

B

OLIGO SEQUENCES -

Original sequences
are in brackets.

Surface property.

1	(CG) CTGAGTTCCAGCACACCGTCAC	Pocket
2	(CA) TCAGGGCGCCGCAGTCCACGA	Flat
3	(T) TGCACGCCGCAGGTCAAGGCG	Convex
4	(CGT) TCCACGACACGCACACCGGTTCG	Flat
5	(GT) CACGCCGCTGCACAGGGCGCCT	Convex
6	(GT) AGCCGGGAAGCAGTGCACGCCG	Pocket
7	(GT) GCAGGTGTAGCACTTCGTGCC	Flat
8	(GT) GTCCACCTTGCAAGTTGCTGGGC	Convex

Fig. 1